Filing Analysis
Acacia Research Corporation held its 2026 Annual Meeting of Stockholders on June 23, 2026. The meeting resulted in the successful election of seven directors and the ratification of Grant Thornton, LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held virtually via live webcast on June 23, 2026.
- Quorum was established with 86,674,540 shares present (out of 96,589,132 outstanding).
- All seven director candidates were elected to serve until the 2027 Annual Meeting.
- Proposal 2: Ratification of Grant Thornton, LLP as independent auditor for FY ending Dec 31, 2026 was approved with 85,775,969 votes in favor.
- Proposal 3: Advisory vote on executive compensation (Say-on-Pay) was approved with 79,726,978 votes in favor.
Acacia Research Corporation filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024. The filing serves as a formal announcement of the company's recent operational and financial performance via a press release.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes Exhibit 99.1 containing the quarterly financial results press release
- Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability
Acacia Research Corporation, through its subsidiary Deflecto Holdco LLC, completed the acquisition of Deflecto Acquisition, Inc. for an aggregate consideration of $103.7 million. The transaction was financed via a combination of cash on hand and a new $48 million term loan.
🚩 Red Flags
- Increased leverage: The acquisition was partially funded by a new $48 million term loan.
- Restrictive Covenants: The new credit agreement includes strict debt-to-EBITDA ratios and fixed charge coverage requirements (minimum 1.20x EBITDA to fixed charges starting Dec 31, 2024).
📋 Key Facts
- Acquisition price: $103.7 million (subject to customary adjustments).
- Financing: Combination of cash on hand and a $48 million secured term loan maturing October 18, 2029.
- Target Company: Deflecto Acquisition, Inc., a manufacturer for commercial transportation, HVAC, and office markets.
- Deflecto Revenue (TTM Aug 31, 2024): ~$131 million.
- Projected 2024 Performance: $128-$136 million in revenue and $17.5-$19.5 million in EBITDA.
- New Credit Facility: $55 million amended/restated credit agreement with JPMorgan Chase Bank, N.A. including a $7 million revolving facility.
Acacia Research Corporation filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024. The filing serves as a formal announcement of the company's recent operational and financial performance via a press release.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing is made pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were released via press release attached as Exhibit 99.1
Acacia Research Corporation filed an amendment to its April 17, 2024, 8-K to provide required financial statements and pro forma information regarding the acquisition of upstream assets in Texas and Oklahoma from Revolution Resources II, LLC.
🚩 Red Flags
- None identified in this specific amendment; the filing is a procedural supplement to provide required financial data.
📋 Key Facts
- The transaction was consummated on April 17, 2024 (the 'Closing Date').
- Acquisition target: Substantially all remaining assets and operations owned by Revolution II WI Holding Company, LLC.
- Assets include upstream assets and related facilities located in Texas and Oklahoma.
- The acquisition was executed through a subsidiary, BE Anadarko II, LLC (a majority-owned subsidiary of Benchmark Energy II, LLC).
- Filing includes audited consolidated financial statements for Revolution II WI Holding Company, LLC as of Dec 31, 2023 (Exhibit 99.1) and unaudited pro forma condensed combined financial statements for Acacia Research Corporation (Exhibit 99.2).
Acacia Research Corporation held its 2024 Annual Meeting of Stockholders on May 21, 2024. The filing reports the results of shareholder votes regarding director elections, auditor ratification, executive compensation, and a new stock incentive plan.
📋 Key Facts
- Annual Meeting held virtually on May 21, 2024.
- Quorum established with 90,483,259 shares present (out of 100,021,951 outstanding).
- Seven directors were elected to the Board of Directors through the 2025 Annual Meeting.
- Ratification of Grant Thornton, LLP as independent auditor for fiscal year ending Dec 31, 2024 was approved with 89,921,255 votes in favor.
- The 2024 Stock Incentive Plan was approved by shareholders.
- Say-on-pay (executive compensation) was approved on a non-binding basis.
Acacia Research Corporation filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2024. This is a routine regulatory filing used to communicate financial results to the market.
📋 Key Facts
- The filing was made on May 9, 2024.
- The report pertains to the quarterly financial results for the period ending March 31, 2024.
- Financial results were released via a press release furnished as Exhibit 99.1.
Acacia Research Corporation's subsidiary, Benchmark Energy II, LLC, completed the acquisition of upstream oil and gas assets in Texas and Oklahoma for $145 million. To fund this transaction, the company utilized a combination of cash on hand, external investor capital, and a newly established $150 million revolving credit facility.
🚩 Red Flags
- Increased leverage via a new $150 million revolving credit facility secured by all assets of BE Anadarko and guarantors.
- The loan agreement includes customary restrictive covenants (limitations on indebtedness, liens, dividends, etc.) and financial ratio requirements.
📋 Key Facts
- Acquisition price: $145 million in total.
- Assets acquired include ~140,000 net acres and interest in ~470 operated producing wells in Texas and Oklahoma.
- Funding breakdown: $59.9 million from Acacia Research (cash on hand), $15.25 million from other investors (including McArron Partners), and the remainder via a new revolving credit facility.
- New Revolving Credit Facility: $150 million maximum aggregate amount with Frost Bank; ~$85 million available at closing.
- Acacia Research's interest in Benchmark is approximately 73.5% following the transaction.
This is an 8-K/A (Amendment) filed by Acacia Research Corporation to correct a previous filing from the same date. The amendment's sole purpose is to remove Item 8.01, which was included in error in the original report.
🚩 Red Flags
- None identified; this is a corrective administrative amendment.
📋 Key Facts
- The filing is an Amendment (Form 8-K/A) to an Original Form 8-K filed on March 14, 2024.
- The amendment removes Item 8.01 from the original filing due to inadvertent inclusion.
- The company furnished a press release regarding financial results for the year ended December 31, 2023, under Item 2.02.
Acacia Research Corporation filed an 8-K to furnish its year-end financial results for the period ending December 31, 2023. The filing also provides a reminder regarding a previously approved $20 million stock repurchase program.
📋 Key Facts
- Announced full-year 2023 financial results via press release on March 14, 2024.
- Reiterated the November 9, 2023 Board approval of a $20 million stock repurchase program.
- The repurchase program is capped at 5,800,000 shares and has no expiration date.
Acacia Research Corporation's majority-owned subsidiary, Benchmark Energy II, LLC, entered into a definitive agreement to acquire upstream oil and gas assets in Texas and Oklahoma for $145 million. The transaction is expected to close in Q2 2024.
🚩 Red Flags
- Significant cash outlay ($57.5M) representing a substantial portion of the company's reported liquidity profile (implied by 'cash on hand' description).
- Transaction includes complex termination rights related to title and environmental defects exceeding 15% of purchase price.
📋 Key Facts
- Total purchase price: $145 million in cash (subject to customary adjustments).
- Acacia's direct contribution to fund Benchmark: $57.5 million, intended to be sourced from cash on hand.
- Funding structure: $57.5M from Acacia, ~$72.5M via a new revolving credit agreement by Benchmark, and ~$15M from McArron Partners.
- Deposit: $10.875 million (7.5% of purchase price) placed in escrow.
- Target assets: Upstream assets and related facilities in Texas and Oklahoma.
- Expected closing: Second quarter of 2024.
Acacia Research Corporation announced the resignation of director Jonathan Sagal and the appointment of Ajay Sundar, a Managing Director at Starboard Value LP, to its Board of Directors.
📋 Key Facts
- Jonathan Sagal resigned from the Board effective February 13, 2024; resignation was not due to any disagreement with the company.
- Ajay Sundar appointed as a director on February 13, 2024, serving until the 2024 annual meeting of stockholders or successor election.
- Ajay Sundar is currently a Managing Director at Starboard Value LP.
- Mr. Sundar will receive standard non-employee director compensation as per the company's 2023 proxy statement.
Acacia Research Corporation has appointed Martin D. McNulty, Jr. as Chief Executive Officer on a permanent basis, ending his tenure as Interim CEO which began in November 2022. The Board also expanded its size from six to seven directors with Mr. McNulty's appointment.
📋 Key Facts
- Martin D. McNulty, Jr. appointed as permanent CEO effective February 13, 2024.
- Annual salary set at $500,000.
- Eligible for annual bonus between 100-150% of base salary based on Board performance objectives.
- Performance-based RSU vesting tied to Company's compound annual growth rate (CAGR) of adjusted book value per share through Dec 31, 2025.
- Board size expanded from six to seven directors; McNulty appointed as a director until the 2024 annual meeting.
- Termination benefits include 1.5x base salary paid over 18 installments and up to 18 months of subsidized health/welfare payments.
Acacia Research Corporation completed the sale of its entire stake in Arix Bioscience PLC on January 19, 2024. The transaction involved 33,023,210 shares for a total consideration of approximately $57.08 million.
📋 Key Facts
- Completed the sale of 33,023,210 shares of Arix Bioscience PLC (Arix) on January 19, 2024.
- Total aggregate sale price: $57,078,670.12.
- Sale price per share: £1.43 (equivalent to ~$1.73 USD based on exchange rate of 1.2087 USD/GBP).
- Buyer: RTW Biotech Opportunities Operating Ltd (a subsidiary of RTW Biotech Opportunities Limited).
- Acacia Research Corporation no longer holds any shares in Arix Bioscience PLC.